Indevus begins study of Sanctura XR bladder treatment
12th Sep 2005, 13:51 GMT
Indevus Pharmaceuticals has initiated a phase III clinical program for Sanctura XR in patients with overactive bladder, triggering a $10 million milestone payment from Esprit Pharma.
Latest news from Pharmaceutical Business Review Online:
- Celesio revenues, profits up
- Amgen arthritis drug shows sustained safety and efficacy
- Study supports cardiovascular safety of naproxen
- Cangene chickenpox drug granted orphan status
- Reata brain cancer therapy shows strong activity
- Novartis diabetes drug faces three month delay
- Favrille drug fails secondary goal
- Neurogen commences human testing of obesity drug
- Aeterna prostate cancer drug shows promise
- Isis says new drug effective against cholesterol